Empyema after lung resection is a challenging condition to manage and is associated with a high mortality. Intrathoracic application of a vacuum-assisted closure (VAC) device is recently introduced as an adjunct in the management of this condition. A best evidence topic was constructed to address whether this approach is effective in successful chest closure and reducing hospital stay. Twenty-three papers were found using the reported search, of which nine papers were identified that provided the best evidence to answer the question. All papers were retrospective and included a total of 69 patients treated with intrathoracic VAC. There was only one cohort study and the rest were either case series or case reports. In a cohort of 19 patients reported by Palmen et al. the average duration of an open window thoracostomy in a group of patients with VAC (n = 11) was 39 ± 17 days and in those without VAC (n = 8) was 933 ± 1422 days. Median length of VAC treatment was 22 days (range 6-66 days) in a series of 28 patients reported by Saadi et al. Some authors excluded patients with a bronchopleural fistula (BPF) from VAC treatment. However, Groetzner et al. have safely used VAC in patients with BPF after covering the bronchus stump with an intrathoracic muscle flap. The mediastinum and the bronchus can be covered using a polyvinyl-alcohol foam. Polyurethane foam is commonly used to fill the intrathoracic cavity up to the superficial wound. The suggested starting level of negative pressure is as low as -25 mmHg to -75 mmHg depending on the presence or absence of signs of mediastinal traction; this negative pressure can gradually be increased to -125 mmHg over time. The recommended interval between VAC changes is two to five days. Accumulated evidence in this article, although limited, suggests that VAC, as an adjunct to the standard treatment, can potentially alleviate the morbidity and decrease hospital stay in patients with empyema after lung resection. VAC can reduce inpatient length of treatment and can make the condition manageable in an outpatient setting. These results are yet to be proven by larger studies and clinical trials.
Introduction
A best evidence topic was constructed according to a structured protocol as described in ICVTS [1] .
Clinical scenario
A 75-year-old male presented with fever, dyspnea, and leukocytosis, three months after a right lower lobectomy for adenocarcinoma. He had similar presentations about one month ago and was diagnosed with postlobectomy empyema (PLE) for which he was treated with decortication, pleural irrigation, and antibiotics and was discharged in good health. A thoracic computed tomography (CT)-scan this time is suggestive of recurrence of empyema. You plan to take the patient to the theater for an open window thoracostomy. You ponder the safety and efficacy of an intrathoracic application of vacuum-assisted closure (VAC) and conduct a literature search to answer the question.
Three-part question
In [patients with empyema after lung resection] is the [application of a intrathoracic VAC] effective in [successful chest closure and reducing hospital stay]?
Search strategy
Medline (from 1948 to March 2011) were searched using OVID interface for the relevant MESH terms (exp negativepressure wound therapy/or VAC.mp.) or vacuum assist ed. mp. or (((vacuum.mp. or exp vacuum/) and dressing.mp.) or exp bandages/) and (empyema.mp. or exp Empyema, pleural/or exp Empyema/or exp pleural diseases/or pleural space infection.mp.). 
Search results
Twenty-three papers were found using the reported search. From these, nine papers were identified that provided the best evidence to answer the clinical question (Table 1) .
Results
Empyema after lung resection is a challenging condition to manage and is associated with a high mortality [11] . A variety of techniques are suggested for the management of a postpneumonectomy empyema (PPE) or PLE. Some of these techniques include open pleural drainage, irrigation of the pleural space with antibiotic solution, thoracoplasty, open window thoracostomy, and obliteration of the residual space with a transposed chest wall muscle [12] [13] [14] [15] [16] . Varker and Ng [10] , for the first time in 2006, described successful use of a intrathoracic VAC in a patient with PLE. A few other authors later reported intrathoracic application of VAC in single cases [8] [9] [10] or series [2] [3] [4] [5] [6] of patients with PLE or PPE.
Palmen et al. [4] retrospectively compared the outcome of VAC therapy (n = 11) and conventional methods (n = 8) in patients with PLE, PPE, or de novo empyema. Bronchopleural fistula (BPF) was ruled out in all patients selected for VAC therapy. Surgical decortication was performed in six patients in the VAC group and four patients in the non-VAC group. All patients in the VAC group and two in the non-VAC group had successful closure. The VAC group was considered potentially dischargeable once there was enough evidence of granulation formation in the cavity. Long-term survival rate in the VAC group was significantly better than the non-VAC group.
Of interest, Groetzner et al. [6] included those patients with BPF. All except two patients had their treatment completed as inpatient mostly due to the restrictions imposed by the insurance policies of these patients. VAC changes were done every 48-86 hours under either general anesthesia (72%) or analgo-sedation (28%). Regardless of presence or absence of BPF, all patients had full recovery (85% primary, 15% after second course of VAC therapy for recurrence). Al-Mufarrej et al. [2] also included patients with BPF (4/6). All patients (n = 6) underwent a lateral thoracic window and a modified Eloesser flap and multiple outpatient debridement and Scede partial thoracoplasties with closure of any bronchial fistula. A VAC dressing was applied to the thoracic cavity after each debridement. These procedures were repeated every 7-10 days. All patients were on oral or intravenous antibiotics. One patient had one recurrence and another one had two recurrences. All patients had full recovery regardless of recurrence.
In the largest series presented in 2009 by Saadi et al. [5] , 28 patients underwent surgical debridement and control of underlying pathology. Repeated intrathoracic VAC changes were done under general anesthesia with four-day intervals. The overall success rate was 100% in those who survived (24/28).
Discussion
Intrathoracic use of VAC is a novel idea. Accumulated evidence in this article, although limited, suggests that VAC, as an adjunct to the standard treatment, can potentially alleviate the morbidity and decrease hospital stay in patients with empyema after lung resection. VAC can reduce inpatient length of treatment and can make the condition manageable in an outpatient setting. These results are yet to be proven by larger studies and clinical trials.
